Key terms

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CRNX news

Apr 05 10:40am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 04 5:02pm ET Crinetics Pharmaceuticals Launches New Deferred Compensation Plan by TipRanks Mar 25 4:55am ET JMP Securities biotech analysts to hold an analyst/industry conference call by TipRanks Mar 22 5:12pm ET JMP Securities biotech analysts to hold an analyst/industry conference call by TipRanks Mar 22 11:33am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 21 11:18am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 21 2:36am ET Buy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential by TipRanks Mar 21 2:15am ET Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results by TipRanks Mar 20 8:00am ET Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX) by TipRanks Mar 20 7:43am ET Crinetics price target raised to $55 from $54 at Oppenheimer by TipRanks Mar 20 6:13am ET Crinetics price target raised to $80 from $60 at JMP Securities by TipRanks Mar 20 6:04am ET Crinetics price target raised to $60 from $50 at H.C. Wainwright by TipRanks Mar 20 6:02am ET 3 Best Stocks to Buy Now, 3/20/2024, According to Top Analysts by TipRanks Mar 19 4:16pm ET JonesResearch ups Crinetics target, sees more room to run for shares by TipRanks Mar 19 4:08pm ET Crinetics files to sell 8.33M shares of common stock for holders by TipRanks Mar 19 12:25pm ET Paltusotine: A Potential Game-Changer in Acromegaly Treatment, Analyst Recommends Buy by TipRanks Mar 19 8:40am ET Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB) by TipRanks Mar 19 6:42am ET Crinetics Pharmaceuticals’ Paltusotine Shows Promising Results by TipRanks Mar 19 6:04am ET Crinetics’ paltusotine in acromegaly meets all Phase 3 study endpoints by TipRanks Mar 13 1:20pm ET Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX) by TipRanks Mar 13 7:27am ET Crinetics price target raised to $54 from $48 at Oppenheimer by TipRanks Mar 13 6:20am ET Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA) by TipRanks Mar 13 12:25am ET Buy Rating Affirmed for Crinetics Pharmaceuticals as Paltusotine Shows Promising Phase 2 Results and Market Potential by TipRanks Mar 12 4:44pm ET Crinetics Pharmaceuticals Advances with Promising Phase 2 Results by TipRanks Mar 12 4:11pm ET Crinetics reports topline results from paltusotine study by TipRanks Mar 11 7:01am ET Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Crinetics Pharmaceuticals (CRNX) by TipRanks Mar 08 6:04am ET Crinetics price target raised to $50 from $42 at H.C. Wainwright by TipRanks Mar 06 4:59am ET Crinetics initiated with a Buy at Citi by TipRanks Mar 01 11:04am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 29 2:05pm ET Strong Buy Rating for Crinetics Pharmaceuticals Amidst Financial Fortitude and Promising Clinical Trials by TipRanks Feb 29 8:10am ET Analysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX) by TipRanks

No recent press releases are available for CRNX

CRNX Financials

1-year income & revenue

Key terms

CRNX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CRNX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days